Plasma Fractionation Market Research Trends and Growth Prospects to 2035

Plasma Fractionation Market Overview

The Plasma Fractionation Market focuses on the collection, processing, and separation of human blood plasma into valuable therapeutic proteins and plasma-derived medicinal products. Plasma fractionation plays a critical role in producing products such as immunoglobulins, albumin, coagulation factors, and protease inhibitors, which are widely used to manage immunodeficiency disorders, hemophilia, autoimmune diseases, neurological conditions, and other serious medical conditions. The increasing need for plasma-derived therapies, improvements in plasma collection infrastructure, and technological advancements in fractionation and purification processes are supporting market expansion.

Get Free Sample PDF Brochure:
https://www.marketresearchfuture.com/sample_request/7397

Market Drivers

Rising Prevalence of Immunodeficiency and Autoimmune Disorders

The increasing prevalence and improved diagnosis of immunodeficiency and autoimmune diseases are major factors driving demand for plasma-derived therapies. Immunoglobulin products are widely used in the management of immune deficiencies and several autoimmune and neurological conditions, creating sustained demand for plasma fractionation.

Growing Demand for Plasma-Derived Therapies

Plasma-derived products such as immunoglobulins, albumin, and coagulation factors are essential in the treatment of a wide range of chronic, rare, and life-threatening conditions. Growing clinical applications of these products are expanding the demand for plasma fractionation globally.

Increasing Plasma Collection Capacity

Expansion of plasma collection centers and investments in plasma-processing infrastructure are strengthening the supply chain for plasma-derived medicines. Governments and healthcare organizations are increasingly focusing on domestic plasma supply and self-sufficiency to improve the availability of essential therapies.

Technological Advancements in Fractionation

Advances in chromatography, filtration, centrifugation, and precipitation technologies are improving the efficiency and recovery of plasma proteins. Modern purification technologies can also support enhanced product quality and pathogen-safety processes, creating opportunities for market growth.

Growing Healthcare Expenditure

Increasing healthcare expenditure and improvements in access to specialized treatments are encouraging the adoption of plasma-derived medicines. As healthcare systems expand access to therapies for rare diseases, immune disorders, and hematological conditions, demand for fractionated plasma products is expected to increase.

Increasing Focus on Rare Disease Treatment

Greater awareness and diagnosis of rare diseases such as hemophilia, primary immunodeficiency disorders, and certain neurological conditions are increasing the need for specialized plasma-derived therapies. This expanding patient population represents an important long-term growth opportunity for the plasma fractionation industry.

Market Challenges

High Cost of Plasma-Derived Products

The collection, testing, transportation, storage, fractionation, and purification of human plasma require sophisticated infrastructure and strict quality-control systems. These requirements can increase production costs and make plasma-derived therapies expensive in some healthcare markets.

Plasma Supply Constraints

The availability of donated plasma is a critical factor affecting the plasma fractionation industry. Disruptions in plasma collection, donor shortages, regulatory restrictions, or unexpected healthcare emergencies can affect the supply of raw plasma and subsequently influence production capacity.

Complex Regulatory Requirements

Plasma collection and fractionation are subject to stringent safety and quality regulations. Manufacturers must comply with requirements covering donor screening, plasma testing, pathogen control, manufacturing processes, storage, and distribution, increasing the complexity of operations.

High Capital Investment

Establishing plasma collection centers and fractionation facilities requires significant investment in specialized equipment, manufacturing infrastructure, quality-control laboratories, and cold-chain systems. These capital requirements can create barriers for new market participants.

Risk of Supply Chain Disruptions

The global plasma fractionation supply chain depends on plasma collection networks, specialized transportation, storage infrastructure, and highly regulated manufacturing facilities. Disruptions at any stage can affect the availability of critical plasma-derived products.

Browse In-depth Market Research Report on Plasma Fractionation Market:
https://www.marketresearchfuture.com/reports/plasma-fractionation-market-7397

Market Segmentation

By Product Type:

Immunoglobulin: Immunoglobulins represent a major product category in plasma fractionation and are used to treat immune deficiencies, autoimmune disorders, and certain neurological conditions. The segment is supported by increasing demand for immunoglobulin replacement and immune-modulating therapies.

Albumin: Albumin is widely used in critical care, fluid management, surgery, trauma treatment, and several other medical applications. Its established clinical use makes it an important product in the plasma fractionation market.

Coagulation Factors: Coagulation factors, including factor VIII and other clotting proteins, are essential in the treatment of bleeding disorders such as hemophilia.

Protease Inhibitors: Protease inhibitors are used in specialized therapeutic applications and represent an additional product category derived from human plasma.

By Application:

Neurology: Plasma-derived products are increasingly used in the treatment of neurological disorders, including certain immune-mediated neurological conditions.

Hematology: Plasma fractionation products play an important role in managing bleeding disorders and other hematological conditions.

General Medicine: Albumin and other plasma-derived products have broad applications across general medical and critical-care settings.

Immunology: Immunology is a major application area, supported by growing demand for immunoglobulin therapies for immune deficiencies and autoimmune conditions. MRFR reports that immunology accounted for approximately 45% of the market in 2024.

By End User:

Hospitals: Hospitals represent a major end-user segment because plasma-derived products are widely administered in inpatient, emergency, surgical, and critical-care settings.

Ambulatory Surgical Centers: The growing adoption of outpatient procedures is increasing the use of plasma-derived therapies in ambulatory healthcare environments.

Blood Banks: Blood banks and plasma collection organizations play an important role in supplying plasma used for fractionation and downstream therapeutic production.

Pharmaceutical Companies: Pharmaceutical companies and plasma fractionators use specialized facilities to process plasma and manufacture therapeutic proteins.

By Technology:

Centrifugation: Centrifugation is used to separate blood components and is an important technology within plasma processing.

Chromatography: Chromatography enables the separation and purification of specific plasma proteins and is becoming increasingly important in advanced fractionation processes.

Precipitation: Precipitation techniques are used to separate proteins based on their physical and chemical characteristics.

Filtration: Filtration technologies support plasma purification and processing and can contribute to efficient protein recovery.

By Region:

North America: North America represents a leading regional market due to advanced healthcare infrastructure, established plasma collection networks, high demand for plasma-derived therapies, and significant industry investment.

Europe: Europe has a strong plasma fractionation industry supported by established pharmaceutical companies, advanced healthcare systems, regulatory frameworks, and demand for immunoglobulin and other plasma-derived products.

Asia-Pacific: Asia-Pacific is expected to witness significant growth due to increasing healthcare expenditure, improving access to specialized treatments, growing awareness of plasma donation, and rising demand for therapies for rare and chronic diseases.

Latin America, Middle East & Africa: Emerging markets in these regions are gradually expanding healthcare infrastructure and access to plasma-derived therapies, creating additional opportunities for market participants.

Regional Insights

North America:

North America is a leading region in the Plasma Fractionation Market, supported by sophisticated healthcare infrastructure, extensive plasma collection networks, and high demand for plasma-derived medicines. According to MRFR, North America accounted for more than 45% of global market revenue in 2024, generating approximately USD 14.3 billion.

Europe:

Europe represents another important market due to its established pharmaceutical and biotechnology industry and strong demand for plasma-derived therapies. MRFR estimates that the European market was valued at approximately USD 9.55 billion in 2024, representing around 30% of the global market.

Asia-Pacific:

The Asia-Pacific market is expanding as countries such as China, India, Japan, and South Korea increase investments in healthcare infrastructure and specialized pharmaceutical manufacturing. Growing awareness of plasma donation and increasing demand for immunoglobulin and albumin therapies are expected to create significant opportunities.

Rest of the World:

Latin America, the Middle East, and Africa are emerging markets where improvements in healthcare infrastructure, greater awareness of plasma-derived therapies, and increasing investments in pharmaceutical manufacturing are expected to support future growth.

Key Players

  • Grifols
  • CSL Behring
  • Takeda Pharmaceutical Company Limited
  • Octapharma
  • Kedrion S.p.A.
  • Biotest AG
  • LFB Group
  • Hualan Biological Engineering Inc.

MRFR identifies Grifols, CSL Behring, Takeda Pharmaceutical Company Limited, Octapharma, Kedrion, Biotest, LFB Group, and Hualan Biological Engineering among the major participants in the global Plasma Fractionation Market.

Future Outlook

The Plasma Fractionation Market is expected to experience substantial growth as demand for immunoglobulins, albumin, coagulation factors, and other plasma-derived therapies continues to increase. MRFR’s current report projects the market to reach USD 64.22 billion by 2035, with a 6.59% CAGR during 2025–2035 based on its current 2024–2035 forecast.

Future opportunities are expected to emerge from the expansion of plasma collection infrastructure, development of innovative plasma-derived therapies for rare diseases, increasing use of automated collection and processing technologies, and greater investment in domestic plasma supply. The industry is also moving toward more advanced purification approaches, including chromatography-based technologies designed to improve recovery and processing efficiency.

Growing government interest in plasma self-sufficiency and healthcare supply security is expected to further encourage investments in domestic collection and fractionation capabilities. By 2035, continued technological innovation, increasing therapeutic applications, and expanding access to plasma-derived medicines are expected to strengthen the industry’s long-term growth prospects.

Explore key developments shaping industry transformation:

Health Information Exchange Market Volume

Health Information Exchange Market Forecast

Health Information Exchange Market Outlook

Healthcare Compliance Software Market Analysis

Healthcare Compliance Software Market Distribution

About Market Research Future:

Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing optimal-quality research and granular research to clients. Its market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country-level market segments enable clients to see more, know more, and do more, helping answer their most important questions.

Follow Us: LinkedIn | Twitter

Contact:

Market Research Future (Part of Wantstats Research and Media Private Limited)

99 Hudson Street, 5th Floor

New York, NY 10013

United States of America

+1 628 258 0071 (US)

+44 2035 002 764 (UK)

Email: sales@marketresearchfuture.com

Website: Market Research Future

    Written by

    Market Research Future

    Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis regarding diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.

    Leave a Comment